Dual role for lung cancer molecule
Nature Communications
March 4, 2015
A tumour suppressive role for a molecule previously believed to contribute to the progression of lung cancer has been revealed, in a mouse model, this week in Nature Communications. This new role applies specifically to mutations often found in patients with a history of smoking.
The molecule, STAT3, mediates cellular responses to extracellular stimuli and is often activated in lung cancer. For this reason current therapies are being developed to specifically inhibit STAT3. However, Emilio Casanova and colleagues show that STAT3 also acts as a tumour suppressor when combined with certain mutations of the KRAS oncogene, which are often found in lung cancer patients with a history of smoking. Low STAT3 levels were found in lung cancer patients with advanced malignancy and poor survival. This suggests that, in this context, inactivation of STAT3 might not be a beneficial therapeutic strategy. The newly identified tumour suppressive role for STAT3 presents therapeutic opportunities to treat patients suffering from lung cancer and carrying certain mutations.
doi: 10.1038/ncomms7285
Research highlights
-
Jan 13
Genetics: Correcting for genetic associations between alcohol and diseaseNature Communications
-
Dec 23
Biomedical engineering: Tiny device goes with the (blood) flowNature Communications
-
Dec 21
Epidemiology: Underdetection of COVID-19 after the first lockdown in FranceNature
-
Dec 18
Geology: Alpine summits may have been ice-free during life of Tyrolean IcemanScientific Reports
-
Dec 17
Epidemiology: Mapping gaps in measles vaccination coverageNature
-
Dec 17
Neuroscience: When you’re smiling, the whole world smiles with youNature
